Literature DB >> 21464409

Vatalanib in advanced colorectal cancer: two studies with identical results.

Alberto F Sobrero, Paolo Bruzzi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21464409     DOI： 10.1200/JCO.2010.33.2429

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  9 in total

1.  Novel Therapies in Development for Metastatic Colorectal Cancer.

Authors:  Michael S Lee; Scott Kopetz
Journal:  Gastrointest Cancer Res       Date:  2014-09

2.  A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumors.

Authors:  Justine Yang Bruce; Patricia M LoRusso; Priscila H Goncalves; Elisabeth I Heath; Elizabeth Sadowski; David R Shalinsky; Yanwei Zhang; Anne M Traynor; Aurora Breazna; Alejandro D Ricart; Michael Tortorici; Glenn Liu
Journal:  Cancer Chemother Pharmacol       Date:  2016-01-20       Impact factor: 3.333

3.  A synthetic dl-nordihydroguaiaretic acid (Nordy), inhibits angiogenesis, invasion and proliferation of glioma stem cells within a zebrafish xenotransplantation model.

Authors:  Xiaojun Yang; Wei Cui; Shicang Yu; Chuan Xu; Guilai Chen; Ai Gu; Tingting Li; Youhong Cui; Xia Zhang; Xiuwu Bian
Journal:  PLoS One       Date:  2014-01-15       Impact factor: 3.240

Review 4.  Recent developments in receptor tyrosine kinases targeted anticancer therapy.

Authors:  Samir H Raval; Ratn D Singh; Dilip V Joshi; Hitesh B Patel; Shailesh K Mody
Journal:  Vet World       Date:  2016-01-29

Review 5.  Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics.

Authors:  Ahmed M E Abdalla; Lin Xiao; Muhammad Wajid Ullah; Miao Yu; Chenxi Ouyang; Guang Yang
Journal:  Theranostics       Date:  2018-01-01       Impact factor: 11.556

6.  Towards shedding some light on regorafenib treatment in refractory metastatic colorectal cancer.

Authors:  Gerald Prager; Guillem Argilés
Journal:  ESMO Open       Date:  2017-07-29

7.  Decreased efficacy of drugs targeting the vascular endothelial growth factor pathway by the epigenetic silencing of FLT1 in renal cancer cells.

Authors:  Jee Yeon Kim; Junha Hwang; Seo Hyun Lee; Hyo Jin Lee; Jaroslav Jelinek; Hyeseon Jeong; Jae Sung Lim; Jin Man Kim; Kyu Sang Song; Byung Hoon Kim; Sukhoon Lee; Jei Kim
Journal:  Clin Epigenetics       Date:  2015-09-16       Impact factor: 6.551

8.  Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205.

Authors:  T Hoehler; G von Wichert; C Schimanski; S Kanzler; M H Moehler; A Hinke; T Seufferlein; J Siebler; A Hochhaus; D Arnold; M Hallek; R Hofheinz; U T Hacker
Journal:  Br J Cancer       Date:  2013-08-20       Impact factor: 7.640

Review 9.  Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next?

Authors:  E Una Cidon; P Alonso; B Masters
Journal:  Clin Med Insights Oncol       Date:  2016-04-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.